BeyondSpring to Host Second Quarter Financial Results and Corporate Update Conference Call on September 10, 2021

Rhea-AI Summary

BeyondSpring Inc. (NASDAQ: BYSI) will host a conference call on September 10, 2021, at 8:00 AM ET to discuss financial results for Q2 2021 and recent corporate updates. Notably, BeyondSpring's lead asset, plinabulin, is progressing in clinical trials, aiming for approval to prevent chemotherapy-induced neutropenia. The company has received Priority Review and breakthrough designation in the U.S. and China, with a PDUFA date set for November 30, 2021. The conference can be accessed via phone or webcast, with an archived replay available on its website.

Positive

• Lead asset plinabulin has received Priority Review and breakthrough designation in the U.S. and China.
• PDUFA date for plinabulin's approval is set for November 30, 2021.
• DUBLIN-3 study met its primary endpoint, indicating overall survival benefits for plinabulin.

Negative

• None.

NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that management will host a conference call to report its financial results for the second quarter ended June 30, 2021 and provide an update on recent corporate events on Friday, September 10, 2021 at 8:00 AM Eastern Time. Details for the conference call are below:

Friday, September 10 @ 8:00 AM Eastern Time
Domestic:	877-451-6152
International:	201-389-0879
Conference ID:	13722968
Webcast:	http://public.viavid.com/index.php?id=146495

An archived replay of the webcast will be available for 90 days on BeyondSpring’s website at www.beyondspringpharma.com under “Events & Presentations” in the Investors section.

About BeyondSpring
Headquartered in New York City, BeyondSpring is a global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes for patients who have high unmet medical needs. BeyondSpring’s first-in-class lead asset plinabulin, is being developed as a “pipeline in a drug” in various cancer indications as direct anti-cancer agent and to prevent chemotherapy induced neutropenia (CIN). Plinabulin and G-CSF combination has filed for approval and has received Priority Review and breakthrough designation in the U.S. and China for the prevention of CIN with a PDUFA date of November 30, 2021 in the U.S.  In DUBLIN-3 study, a global, randomized, active controlled Phase 3 study, plinabulin and docetaxel combination has met the primary endpoint of extending overall survival compared to docetaxel alone, in 2^nd/3^rd line NSCLC (EGFR wild type). Additionally, it is being broadly studied in combination with various immuno-oncology regimens that could boost the efficacy of PD-1 / PD-L1 antibodies in seven different cancers. In addition to plinabulin, BeyondSpring’s extensive pipeline includes three pre-clinical immuno-oncology assets and a subsidiary, SEED Therapeutics, which is leveraging a proprietary targeted protein degradation drug discovery platform.

Investor Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
+1 617-430-7577
arr@lifesciadvisors.com

Media Contact:
Darren Opland, Ph.D.
LifeSci Communications
+1 646-627-8387
darren@lifescicomms.com

 

FAQ

What are the details of BeyondSpring's upcoming conference call on September 10, 2021?

BeyondSpring will host a conference call on September 10, 2021, at 8:00 AM ET to discuss Q2 2021 financial results and corporate updates.

What is the significance of the PDUFA date for plinabulin?

The PDUFA date for plinabulin is November 30, 2021, marking a crucial milestone for its approval to prevent chemotherapy-induced neutropenia.

What were the results of the DUBLIN-3 study for plinabulin?

The DUBLIN-3 study demonstrated that plinabulin in combination with docetaxel met the primary endpoint of extending overall survival compared to docetaxel alone.